Accessibility Menu
Cryosite logo

Cryosite(ASX) CTE

Market CapA$61.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)+405%
5 Year+229%
1 Year+89%
1 Month+0%
A$1.25
+0.00%
+0.00Today
Cryosite last closing stock price
MetricPriceDate
Last closeAUD 1.252026-08-12
Cryosite stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.17%AUD 1.202026-07-21
1 month+0%AUD 1.252026-06-30
3 month+25%AUD 1.002026-05-11
Year to date+25%AUD 1.002025-12-29
1 year+89.39%AUD 0.662025-08-12
3 year+119.64%AUD 0.572023-08-10
5 year+228.63%AUD 0.382021-08-13
Since inception+404.98%AUD 0.252002-05-09

Cryosite Financials at a Glance

Market Cap

A$61.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$28.60M

Net Income (TTM)

A$4.02M

EPS (TTM)

A$0.04

P/E Ratio

27.90

Dividend

A$0.00

Beta (Volatility)

0.09 (Low)

Price

A$1.25

Volume

0

Open

A$1.25

Previous Close

A$1.25

Daily Range

A$1.25 - A$1.27

52-Week Range

A$0.74 - A$1.32

Estimated Earnings Date

Feb 18, 2026

CTE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cryosite

Cryosite Limited is a specialized provider of outsourced logistics and storage solutions for the life sciences industry in Australia. Established in 1999, the company operates through two main divisions: Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage.

Products and Services
  • Temperature-controlled and general biological storage solutions
  • End-to-end supply chain management for clinical research
  • Cryogenic preservation of cord blood and tissue samples
Growth Outlook
  • Recent quarterly revenue reached AUD 8.27 million, a significant increase
  • Net income for the latest quarter was AUD 1.14 million, reflecting strong profitability
  • Operating income margin improved to 19.07%, indicating operational efficiency
Financial Highlights
  • Trailing twelve-month revenue of AUD 30.5 million, showcasing consistent growth
  • Net profit margin of 13.87% demonstrates effective cost management
  • Current ratio of 0.49 indicates a focus on managing short-term liabilities
Cryosite Limited has established itself as a key player in the life sciences logistics sector, providing essential services that support clinical trials and biological storage. The company's recent financial performance highlights its ability to generate revenue and maintain profitability, which may attract potential investors looking for opportunities in the healthcare sector. With a focus on operational efficiency and a growing client base, Cryosite is well-positioned for future growth in a rapidly evolving industry.
AI Generated • Aug 3, 2026

Industry

Life Sciences Tools and Services

Employees

25

CEO

John Hogg

Headquarters

South Granville, NSW 2142, AU

CTE Financials

Key Financial Metrics (TTM)

Gross Margin

59.01%

Operating Margin

18.84%

Net Income Margin

13.87%

Return on Equity

72.82%

Return on Capital

53.61%

Return on Assets

8.23%

Earnings Yield

3.58%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$61.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

48.81M

Volume

0

Avg. Volume

3.48K

Financials (TTM)

Gross Profit

A$17.19M

Operating Income

A$5.19M

EBITDA

A$6.95M

Operating Cash Flow

A$4.99M

Capital Expenditure

-A$4.49M

Free Cash Flow

A$500.00K

Cash & ST Invst.

A$2.54M

Total Debt

A$8.82M

Cryosite Performance Analysis

Cryosite annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 11,756,850N/A
20232023-06-30AUD 11,935,0001.5%
20242024-06-30AUD 12,612,0005.7%
20252025-06-30AUD 14,116,00011.9%
Cryosite sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-3.0%
Q22024-12-316.9%
Q42025-06-3012.6%
Q22025-12-3110.7%
Cryosite annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD 0.03N/A
20232023-06-30AUD 0.033.6%
20242024-06-30AUD 0.0430.4%
20252025-06-30AUD 0.040.3%
Cryosite sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3017.9%
Q22024-12-31-15.7%
Q42025-06-3020.3%
Q22025-12-318.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$8.27M

+29.2%

Gross Profit

A$4.65M

+30.6%

Gross Margin

56.26%

N/A

Market Cap

A$61.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.44M

N/A

Employees

25

N/A

Net Income

A$1.14M

+34.5%

EBITDA

A$1.93M

+34.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$2.54M

-57.2%

Total Debt

A$8.82M

+249.0%

Accounts Receivable

A$2.59M

+31.9%

Inventory

A$72.00K

-18.2%

Long Term Debt

A$1.96M

-58.4%

Short Term Debt

A$6.86M

+1917.4%

Return on Assets

8.23%

N/A

Return on Invested Capital

19.36%

N/A

Free Cash Flow

-A$2.35M

-317.5%

Operating Cash Flow

A$1.30M

+2.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NUZ.AXNeurizon Therapeutics Limited
A$0.06+1.64%
CMP.AXCompumedics Limited
A$0.23+0.00%
MAP.AXMicroba Life Sciences Limited
A$0.05+0.00%
IIQ.AXINOVIQ Ltd
A$0.20+2.63%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About CTE

What is the current price of Cryosite?

Cryosite is trading at A$1.25 per share.

What is the 52-week range for Cryosite?

Over the past 52 weeks, Cryosite has traded between A$0.74 and A$1.32.

How much debt does Cryosite have?

As of the most recent reporting period, Cryosite reported total debt of A$2.27M.

How much cash does Cryosite have on hand?

Cryosite reported A$5.06M in cash and cash equivalents in its most recent financial results.

What is Cryosite’s dividend yield?

Cryosite does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.